Based on the Kodiak Sciences Inc stock forecast from 3 analysts, the average analyst target price for Kodiak Sciences Inc is USD 7.50 over the next 12 months. Kodiak Sciences Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Kodiak Sciences Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Kodiak Sciences Inc’s stock price was USD 2.30. Kodiak Sciences Inc’s stock price has changed by -13.86% over the past week, -36.46% over the past month and -48.55% over the last year.
No recent analyst target price found for Kodiak Sciences Inc
No recent average analyst rating found for Kodiak Sciences Inc
Company Overview Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Read Less
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) ...Read More
Frequently Asked Questions About Kodiak Sciences Inc (KOD) Stock
Based on ratings from 3 analysts Kodiak Sciences Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, 1 sell and 2 hold ratings.
Unfortunately we do not have enough data on KOD's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for KOD is USD 7.50 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on KOD's stock to indicate if its overvalued.
The last closing price of KOD's stock was USD 2.30.
The most recent market capitalization for KOD is USD 0.19B.
Based on targets from 3 analysts, the average taret price for KOD is projected at USD 7.50 over the next 12 months.
This means that KOD's stock price may go up by +226.09% over the next 12 months.
We can't find any ETFs which contains Kodiak Sciences Inc's stock.
As per our most recent records Kodiak Sciences Inc has 108 Employees.
Kodiak Sciences Inc's registered address is 1200 Page Mill Road, Palo Alto, CA, United States, 94304.
You can get more information about it from Kodiak Sciences Inc's website at https://kodiak.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Kodiak Sciences Inc (KOD) Stock
Based on ratings from 3 analysts Kodiak Sciences Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, 1 sell and 2 hold ratings.
Unfortunately we do not have enough data on KOD's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for KOD is USD 7.50 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on KOD's stock to indicate if its overvalued.
The last closing price of KOD's stock was USD 2.30.
The most recent market capitalization for KOD is USD 0.19B.
Based on targets from 3 analysts, the average taret price for KOD is projected at USD 7.50 over the next 12 months.
This means that KOD's stock price may go up by +226.09% over the next 12 months.
We can't find any ETFs which contains Kodiak Sciences Inc's stock.
As per our most recent records Kodiak Sciences Inc has 108 Employees.
Kodiak Sciences Inc's registered address is 1200 Page Mill Road, Palo Alto, CA, United States, 94304.
You can get more information about it from Kodiak Sciences Inc's website at https://kodiak.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for KOD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
